Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Voyager Therapeutics Q3 2026 Results: Net Loss of $24.7M, Loss Narrows

For the nine months ended September 30, 2026, Voyager Therapeutics reported a net loss of $77.1 million, an improvement from the $92.3 million loss in the same period of 2025. Collaboration revenue decreased significantly to $9.8 million from $25.0 million year-over-year, while total assets declined to $177.1 million as of September 30, 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue4.013.4
Profit before tax-24.7-27.8
Net income-24.7-27.9
EPS (diluted, $ a share)$-0.40$-0.47

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-70.0%
Source

10-Q filed with the SEC, NASDAQ: VYGR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Voyager Therapeutics, Inc.: key numbers

Share price
$1.63Close, Nov 16
Market cap
$101M
Shares outstanding
62.23MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Voyager Therapeutics, Inc.

All →
4:03 PM ET 8-K
Financial Results

Voyager Therapeutics Financial Results

Voyager Therapeutics reported third quarter 2026 financial results, ending the period with $132 million in cash and extending its projected runway into Q2 2028. The company highlighted progress in its Alzheimer’s disease pipeline, with clinical data readouts for VY7523 expected in Q4 2026 and patient dosing for VY1706 anticipated in the coming months.

“There is strong momentum behind our two tau-targeted Alzheimer’s disease programs, and we expect to report PET imaging data from our VY7523 multiple ascending dose trial in the fourth quarter and to dose the first patient with our lead gene therapy VY1706 in the next few months.”

Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager

“During the third quarter, we continued to be disciplined in our operations to reduce year-over-year operating expenses and as a result, we have extended our cash runway into the second quarter of 2028. This strengthens our position as we approach key upcoming milestones.”

Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager
8:07 AM ET 8-K
Executive Compensation

Voyager Therapeutics Executive Compensation

Voyager Therapeutics appointed Robin Swartz as President and announced she will succeed Alfred W. Sandrock, Jr. as CEO in Q1 2027. In connection with the promotion, Swartz entered into an amended employment agreement providing for a $625,000 base salary, a 50% target bonus, and equity grants including 318,500 stock options and 68,250 restricted stock units.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.